---
title: DMARDs
layout: diseases
author: Corbin Cox
last-updated: 2018-7-28
created: 2018-7-28
toc: true
common: false
---

# Traditional DMARDs

## Methotrexate

**MOA: **Inhibition of purine and pyrimidine synthesis (folic acid mimic)

### SEs

* Bone marrow suppression
* N / V / D
* Stomatitis / mucositis
* Hepatic Cirrhosis
* Hepatitis
* Hepatic Fibrosis
* Pneumonitis
* Pulmonary Fibrosis
* Rash
* Urticaria
* Alopecia
* Teratogenicity
* Bone marrow suppression, N / V / D, and stomatitis / mucositis may be improved with folate 1mg QD

### CIs

* Pregnancy
* Lactating
* Chronic liver disease
  * Caution w/ chronic EtOH use
* Immunodeficiency
* Existing blood dyscrasias
* Pleural or peritoneal effusion
* CrCl &lt; 40

### Monitoring

* Baseline
  * CXR
  * CBC w/ Plt
  * SCr
  * Full Hepatic Panel
  * Hep B & C Screening
* Maintenance: CBC, SCr, LFT
  * &lt; 3mo from initiation: q2-4wks
  * 3-6mo: q8-12wks
  * &gt; 6mo: q12wks

## Leflunomide

**MOA: **Prodrug inhibitor of pyrimidine synthesis via dihydroorotate dehydrogenase, leading to inhibition of T-cell proliferation

### SEs

* **Diarrhea**
* **Rash**
* **Alopecia**
* Increased LFTs
* Teratogenic in both males and females
  * Use cholestyramine 8g TID x11d to clear for conception

### CIs

* Pregnancy

### Monitoring

* Baseline
  * CBC
  * SCr
  * LFTs
* Maintenance: Same as MTX

## Hydroxychloroquine

**MOA: **Inhibition of protein secretion by lysosomal accumulation

### SEs

* N / V / D
* Increased skin pigmentation
* Rash
* Alopecia
* Retinal Toxicity
  * Avoid in pts &gt; 70yo
  * Avoid cumulative lifetime dose &gt; 800g

### Monitoring

* Vision exam at baseline and q6-12mo

## Sulfasalazine

**MOA: **Prodrug that surpasses cytokine release from macrophages via an unknown mechanism

### SEs

* N / V / D
* Anorexia
* Rash
* Urticaria
* **Photosensitivity**
* **Sulfa Allergy**
* Leukopenia
* Thrombocytopenia
* Rare Hematologic SEs
  * Aplastic Anemia
  * Hemolytic anemia

### Monitoring

* Baseline
  * LFTs
  * CBC
  * SCr
* Maintenance: Same as MTX

# TNF Antagonists

## Agents

* Etanercept (Enbrel)
* Infliximab (Remicade)
* Adalimumab (Humira)
* Golimumab (Simponi)
* Certolizumab (Cimzia)

## SEs

* HA
* Rash
* URIs
* Injection site reaction
* CHF exacerbation
* Risk of malignancy
* Risk of demyelinating disease

## Precautions / Warnings

* Increased risk of infection
* Not for use w/ anakinra due to increased infection risk
* Demyelinating disorders
* Malignancies
* CHF
* No concurrent live vaccines

## CIs

* See precautions for class above

## Monitoring

* TB skin test before starting therapy

## Golimumab

### Monitoring

* CBC w/ Plt
* LFTs

# IL-1 Receptor Antagonists

## Anakinra (Kineret)

### SEs

* Injection site reaction
* HA
* N / V
* Flu-like SSx
* Hypersentivity to *E. coli* derived proteins
* Increased risk of serious infections
* Neutropenia

### Warning / Precation

* Do not use w/ TNF inhibitors or abatacept due to infection risk

### Monitoring

* Neutrophil count at baseline, monthly x3mo, then q3mo x1yr

# Anti-CD20 Ig

## Rituximab (Rituxan)

**MOA:** Binds CD20 on B cells and activates NK cells against B cells, leading to apoptosis

### SEs

* T umor lysis syndrome 
* Mucocutaneous reactions 
* Viral infection 
* Hypersensitivity 
* Renal toxicity 
* Bowel obstruction 
* Hepatitis B reactivation 
* Cardiac arrhythmia 

### Warnings

* **Black Box:** Fatal infusion reaction, tumor lysis syndrome, and mucocutaneous reactions

### Monitoring

* CBC w/ plts
* SCr
* Vital signs during infusion

# CTLA-4 Antagonist

## Abatacept (Orencia)

**MOA:** Inhibits co-stimulatory signal by binding to CTLA-4 on T<sub>C</sub> cells

### SEs

* HA
* Nausea
* URI
* Nasopharyngitis
* Infusion reaction
* Serious infeciton
* Malignancy

### Warning / Precautions

* Caution in COPD due to infection risk
* No live vaccinations
* Not for use w/ TNF inhibitors or IL-1 antagonists

### Monitoring

* No hematologic monitoring

# IL-6 Inhibitor

## Tocilizumab (Actrema)

### SEs

* Serious infection
* Hepatotoxicity
* Thrombocytopenia
* Neutropenia
* Infusion reactions
* **Lipid abnormalities**
* Intestinal perforation

### Warnings

* **Black Box:** Serious infection

### CIs

* Liver toxicity
* Thrombocytopenia
* Neutropenia

### Monitoring

* Neutrophil Count q4-8wks
* Plt Count q4-8wks
* LFTs q4-8wks
* Lipid Panel: After 4-8wks then q6mo 

# Janus Kinase Inhibitors

## Tofacitinib (Xeljanz)

### SEs

* URI
* HA
* Diarrhea
* Nasopharyngitis

### Warnings / Precautions

* CYP Interactions
* Do not use w/ hepatic impairment
* **Black Box:** Risk of infection and malignancy

### CIs

* Hgb &lt; 9
* ANC &lt; 1000
* Lymphocyte Count &lt; 500

### Monitoring

* Lymphocyte Count at baseline then q3mo
* Neutrophil count at baseline, 4-8wks, then q3mo
* Hgb at baseline, 4-8wks, then q3mo